MAGELLAN HEALTH SERVICES INC Form 10-Q October 27, 2011

Use these links to rapidly review the document <u>TABLE OF CONTENTS</u>

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2011

Or

• TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to Commission File No. 1-6639

MAGELLAN HEALTH SERVICES, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

55 Nod Road, Avon, Connecticut (Address of principal executive offices)

(860) 507-1900

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \acute{y} No o

(IRS Employer Identification No.)

58-1076937

06001

(Zip code)

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes \acute{y} No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ý	Accelerated filer o	Non-accelerated filer o	Smaller reporting company of	0
		(Do not check if a		
		smaller reporting company)		
Indicate by check mark whe	ether the registrant is a shell	company (as defined in Rule 12b-	2 of the Exchange Act). Yes o N	lo ý

The number of shares of the registrant's Ordinary Common Stock outstanding as of September 30, 2011 was 28,468,410.

FORM 10-Q

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

INDEX

PART I Financial Information: Item 1: Financial Statements Consolidated Balance Sheets December 31, 2010 and September 30, 2011 Consolidated Statements of Income For the Three and Nine Months Ended September 30, 2010 and 2011 Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2010 and 2011 Notes to Consolidated Financial Statements Management's Discussion and Analysis of Financial Condition and Results of Operations Item 2: Item 3: Quantitative and Qualitative Disclosures About Market Risk Item 4: Controls and Procedures PART II Other Information: Legal Proceedings Item 1: Item 1A: Risk Factors Item 2: Unregistered Sales of Equity Securities and Use of Proceeds Item 3: Defaults Upon Senior Securities Submission of Matters to a Vote of Security Holders Item 4: Item 5: Other Information Exhibits

Item 6: Signatures

2

Page No.

<u>3</u> 3

<u>43</u>

<u>44</u>

<u>45</u>

<u>45</u> <u>45</u> <u>46</u> <u>46</u>

<u>46</u>

<u>47</u>

<u>48</u>

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

	De	cember 31, 2010	•	otember 30, 2011 naudited)
ASSETS				í í
Current Assets:				
Cash and cash equivalents	\$	337,179	\$	142,365
Restricted cash		116,734		155,559
Accounts receivable, less allowance for doubtful accounts of \$1,985 and \$2,286 at December 31, 2010 and				
September 30, 2011, respectively		106,934		114,436
Short-term investments (restricted investments of \$114,903 and \$140,707 at December 31, 2010 and September 30,				
2011, respectively)		189,530		240,753
Deferred income taxes		28,439		33,541
Other current assets (restricted deposits of \$21,302 and \$21,716 at December 31, 2010 and September 30, 2011,		- ,		/-
respectively)		79,671		72,460
		.,,,.,-		,
Table Convert Acaste		050 407		750 114
Total Current Assets		858,487		759,114
Property and equipment, net		111,814		114,904
Long-term investments (restricted investments of \$84,950 and \$13,396 at December 31, 2010 and September 30, 2011,		04.074		12.200
respectively)		94,974		13,396
Deferred income taxes		825		10.026
Other long-term assets		2,396		10,036
Goodwill		426,939		426,939
Other intangible assets, net		53,997		47,268
Total Assets	\$	1,549,432	\$	1,371,657
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities:				
Accounts payable	\$	31,878	\$	19,249
Accrued liabilities		105,776		108,836
Medical claims payable		142,671		140,976
Other medical liabilities		109,285		95,517
Current maturities of long-term capital lease obligation		559		559
Test Connect Lick little		200.160		265 127
Total Current Liabilities		390,169		365,137
Deferred income taxes		117 500		11,164
Tax contingencies		117,599		109,066
Deferred credits and other long-term liabilities		2,649		6,725
Total Liabilities		510,417		492,092
Preferred stock, par value \$.01 per share				
Authorized 10,000 shares Issued and outstanding none				
Ordinary common stock, par value \$.01 per share				
Authorized 100,000 shares at December 31, 2010 and September 30, 2011 Issued and outstanding 43,687 shares and				
		127		151
33,782 shares at December 31, 2010, respectively, and 45,101 and 28,468 shares at September 30, 2011, respectively		437		451
Multi-Vote common stock, par value \$.01 per share				

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Authorized 40,000 shares Issued and outstanding none				
Other Stockholders' Equity:				
Additional paid-in capital		725,322		794,845
Retained earnings		694,582		794,466
Warrants outstanding		420		
Accumulated other comprehensive income (loss)		9		(293)
Ordinary common stock in treasury, at cost, 9,905 shares and 16,633 shares at December 31, 2010 and September 30,				
2011, respectively		(381,755)		(709,904)
Total Stockholders' Equity		1,039,015		879,565
Total Liabilities and Stockholders' Equity	\$	1.549.432	\$	1,371,657
Tour Elabrides and Decembrates Equity	Ψ	1,519,152	Ψ	1,571,057

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per share amounts)

		Three Months Ended September 30,				Nine Mont Septem			
		2010		2011		2010		2011	
Net revenue	\$	750,319	\$	686,843	\$	2,220,030	\$	2,077,936	
Cost and expenses:									
Cost of care		467,160		448,051		1,416,317		1,323,197	
Cost of goods sold		55,071		57,636		166,138		167,559	
Direct service costs and other operating expenses(1)		141,581		130,038		419,452		393,384	
Depreciation and amortization		13,950		15,069		41,607		43,288	
Interest expense		482		457		1,751		1,422	
Interest income		(846)		(592)		(2,466)		(2,265)	
		677,398		650,659		2,042,799		1,926,585	
		,				_,,. , , , , ,		-,,,	
Income before income taxes		72,921		36,184		177,231		151,351	
Provision for income taxes		28,137		4,829		71,500		51,467	
		,		,				, , , , , , , , , , , , , , , , , , ,	
Net income		44,784		31,355		105,731		99,884	
Other comprehensive income (loss)		280		(380)		21		(302)	
				. ,					
Comprehensive income	\$	45,064	\$	30,975	\$	105,752	\$	99,582	
comprehensive income	Ψ	45,004	Ψ	50,775	Ψ	105,752	Ψ	<i>))</i> ,302	
Weighted average number of common shares									
outstanding basic (See Note B)		33,450		29,900		33,715		31,406	
outstanding basic (see Note B)		55,450		29,900		55,715		51,400	
Weighted average number of common shares									
outstanding diluted (See Note B)		34,171		30,438		34,345		31,988	
Net income per common share basic:	\$	1.34	\$	1.05	\$	3.14	\$	3.18	
Net income per common share diluted:	\$	1.31	\$	1.03	\$	3.08	\$	3.12	
-									

(1)

Includes stock compensation expense of \$3,596 and \$4,425 for the three months ended September 30, 2010 and 2011, respectively, and \$11,830 and \$13,408 for the nine months ended September 30, 2010 and 2011, respectively.

See accompanying notes to consolidated financial statements.

4

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30,

(Unaudited)

(In thousands)

	2010	2011
Cash flows from operating activities:		
Net income	\$ 105,731	\$ 99,884
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	41,607	43,288
Non-cash interest expense	463	320
Non-cash stock compensation expense	11,830	13,408
Non-cash income tax expense	32,260	(248)
Non-cash amortization (accretion) on investments	6,851	9,660
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:		
Restricted cash	62,413	(38,825)
Accounts receivable, net	10,279	(8,439)
Other assets	(4,085)	(751)
Accounts payable and accrued liabilities	889	(10,216)
Medical claims payable and other medical liabilities	(14,085)	(15,463)
Other	126	3,501
Net cash provided by operating activities	254,279	96,119
Cash flows from investing activities:		
Capital expenditures	(32,201)	(38,468)
Acquisitions and investments in businesses, net of cash acquired		(376)
Purchase of investments	(235,420)	(210,890)
Maturity of investments	154,979	231,093
Net cash used in investing activities	(112,642)	(18,641)
Cash flows from financing activities:		
Payments on long-term debt and capital lease obligations	(588)	
Payments to acquire treasury stock	(74,427)	(327,886)
Proceeds from issuance of equity		20,000
Proceeds from exercise of stock options and warrants	23,121	34,755
Other	(1,611)	839
Net cash used in financing activities	(53,505)	(272,292)
Net increase (decrease) in cash and cash equivalents	88,132	(194,814)
Cash and cash equivalents at beginning of period	196,507	337,179
Cash and cash equivalents at end of period	\$ 284,639	\$ 142,365

See accompanying notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2011

(Unaudited)

NOTE A General

Basis of Presentation

The accompanying unaudited consolidated financial statements of Magellan Health Services, Inc., a Delaware corporation ("Magellan"), include the accounts of Magellan, its majority owned subsidiaries, and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company"). The financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the Securities and Exchange Commission's (the "SEC") instructions to Form 10-Q. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The results of operations for the nine months ended September 30, 2011 are not necessarily indicative of the results to be expected for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company has evaluated subsequent events for recognition or disclosure in our consolidated financial statements filed on this Form 10-Q and no events have occurred that require disclosure.

These unaudited consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2010 and the notes thereto, which are included in the Company's Annual Report on Form 10-K filed with the SEC on February 25, 2011.

Business Overview

The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. As a result of certain acquisitions, the Company expanded into radiology benefits management and specialty pharmaceutical management during 2006, and into Medicaid administration during 2009. The Company provides services to health plans, insurance companies, employers, labor unions and various governmental agencies. The Company's business is divided into the following six segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide, or own any provider of, treatment services except as related to the Company's contract to provide managed behavioral healthcare services to

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

Medicaid recipients and other beneficiaries of the Maricopa County Regional Behavioral Health Authority (the "Maricopa Contract"). Under the Maricopa Contract, effective August 31, 2007 the Company was required to assume the operations of twenty-four behavioral health direct care facilities for a transitional period and to divest itself of these facilities over a two year period. All of the direct care facilities were divested as of December 31, 2009.

The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

Commercial. The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations, governmental agencies, and labor unions. Commercial's contracts encompass risk-based, ASO and EAP arrangements.

Public Sector. The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects services provided to recipients under Medicaid and other state sponsored programs under contracts with state and local governmental agencies. Public Sector contracts encompass either risk-based or ASO arrangements.

Radiology Benefits Management

The Radiology Benefits Management segment ("Radiology Benefits Management") generally reflects the management of the delivery of diagnostic imaging services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members. The Company also contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company offers its radiology benefits management services through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services, and through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services.

Specialty Pharmaceutical Management

The Specialty Pharmaceutical Management segment ("Specialty Pharmaceutical Management") comprises programs that manage specialty drugs used in the treatment of complex conditions such as,

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis and other diseases. Specialty pharmaceutical drugs represent high-cost injectible, infused, oral, or inhaled drugs with sensitive handling or storage needs, many of which may be physician administered. Patients receiving these drugs require greater amounts of clinical support than those taking more traditional agents. Payors require clinical, financial and technological support to maximize the value delivered to their members using these expensive agents. The Company's specialty pharmaceutical management services are provided under contracts with health plans, insurance companies, and governmental agencies for some or all of their commercial, Medicare and Medicaid members. The Company's specialty pharmaceutical services include: (i) contracting and formulary optimization programs; (ii) specialty pharmaceutical dispensing operations; (iii) strategic consulting services; and (iv) medical pharmacy management programs.

Medicaid Administration

The Medicaid Administration segment ("Medicaid Administration") generally reflects integrated clinical management services provided to the public sector to manage Medicaid pharmacy, mental health and long-term care programs. The primary focus of the Company's Medicaid Administration unit involves providing pharmacy benefits administration ("PBA") services under contracts with states to Medicaid and other state sponsored program recipients. Medicaid Administration's contracts encompass Fee-For-Service ("FFS") arrangements. In addition to Medicaid Administration's FFS contracts, effective September 1, 2010, Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector's customers.

Corporate

This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

Summary of Significant Accounting Policies

Recent Accounting Pronouncements

In January 2010, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update, ("ASU"), No. 2010-24, "Health Care Entities Presentation of Insurance Claims and Related Insurance Recoveries" ("ASU 2010-24"). ASU 2010-24 clarifies that a health care entity should not net insurance recoveries against a related claim liability. Additionally, the amount of the claim liability should be determined without consideration of insurance recoveries. This guidance is effective for fiscal years beginning after December 15, 2010. Accordingly, the Company adopted ASU 2010-24 on January 1, 2011. The adoption of this standard did not have a material impact on the consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, "Comprehensive Income (Topic 220): Presentation of Comprehensive Income" ("ASU 2011-05"). ASU 2011-05 requires an entity to present the total of comprehensive income, the components of net income, and the components of other

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements and eliminates the option to present the components of other comprehensive income as part of the statement of equity. ASU 2011-05 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2011, with early adoption permitted. While the adoption of this guidance is expected to impact the Company's disclosures for annual and interim filings for the year ending December 31, 2012, it will not have an impact on the Company's results of operations or financial condition.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, stock compensation assumptions, tax contingencies and legal liabilities. Actual results could differ from those estimates.

Managed Care Revenue

Managed care revenue, inclusive of revenue from the Company's risk, EAP and ASO contracts, is recognized over the applicable coverage period on a per member basis for covered members. The Company is paid a per member fee for all enrolled members, and this fee is recorded as revenue in the month in which members are entitled to service. The Company adjusts its revenue for retroactive membership terminations, additions and other changes, when such adjustments are identified, with the exception of retroactivity that can be reasonably estimated. The impact of retroactive rate amendments is generally recorded in the accounting period that terms to the amendment are finalized, and that the amendment is executed. Any fees paid prior to the month of service are recorded as deferred revenue. Managed care revenues approximated \$610.3 million and \$1,784.9 million for the three and nine months ended September 30, 2010, respectively, and \$533.3 million and \$1,627.9 million for the three and nine months ended September 30, 2011, respectively.

Fee-For-Service and Cost-Plus Contracts

The Company has certain FFS contracts, including cost-plus contracts, with customers under which the Company recognizes revenue as services are performed and as costs are incurred. Revenues from fee-for-service and cost-plus contracts approximated \$47.0 million and \$145.3 million for the three and nine months ended September 30, 2010, respectively, and \$45.0 million and \$131.3 million for the three and nine months ended September 30, 2011, respectively.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

Block Grant Revenues

The Maricopa Contract is partially funded by federal, state and county block grant money, which represents annual appropriations. The Company recognizes revenue from block grant activity ratably over the period to which the block grant funding applies. Block grant revenues were approximately \$26.0 million and \$82.8 million for the three and nine months ended September 30, 2010, respectively, and \$31.8 million and \$85.0 million for the three and nine months ended September 30, 2011, respectively.

Dispensing Revenue

The Company recognizes dispensing revenue, which includes the co-payments received from members of the health plans the Company serves, when the specialty pharmaceutical drugs are shipped. At the time of shipment, the earnings process is complete; the obligation of the Company's customer to pay for the specialty pharmaceutical drugs is fixed, and, due to the nature of the product, the member may neither return the specialty pharmaceutical drugs nor receive a refund. Revenues from the dispensing of specialty pharmaceutical drugs on behalf of health plans were \$58.6 million and \$178.3 million for the three and nine months ended September 30, 2010, respectively, and \$61.8 million and \$178.7 million for the three and nine months ended September 30, 2011, respectively.

Performance-Based Revenue

The Company has the ability to earn performance-based revenue under certain risk and non-risk contracts. Performance-based revenue generally is based on either the ability of the Company to manage care for its clients below specified targets, or on other operating metrics. For each such contract, the Company estimates and records performance-based revenue after considering the relevant contractual terms and the data available for the performance-based revenue calculation. Pro-rata performance-based revenue is recognized on an interim basis pursuant to the rights and obligations of each party upon termination of the contracts. Performance-based revenues were \$2.9 million and \$8.7 million for the three and nine months ended September 30, 2010, respectively, and \$2.4 million and \$15.6 million for the three and nine months ended September 30, 2011, respectively.

Significant Customers

Consolidated Company

The Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the nine months ended September 30, 2010 and 2011.

Pursuant to the Maricopa Contract, the Company provides behavioral healthcare management and other related services to approximately 719,000 members in Maricopa County, Arizona. Under the Maricopa Contract, the Company is responsible for providing covered behavioral health services to persons eligible under Title XIX (Medicaid) and Title XXI (State Children's Health Insurance Program) of the Social Security Act, non-Title XIX and non-Title XXI eligible children and adults with a serious mental illness, and to certain non-Title XIX and non-Title XXI adults with behavioral health

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

or substance abuse disorders. The Maricopa Contract began on September 1, 2007 and extends through September 30, 2013 unless sooner terminated by the parties. The State of Arizona has the right to terminate the Maricopa Contract for cause, as defined, upon ten days' notice with an opportunity to cure, and without cause immediately upon notice from the State. The Maricopa Contract generated net revenues of \$602.4 million and \$570.1 million for the nine months ended September 30, 2010 and 2011, respectively.

One of the Company's top ten customers during 2010 was WellPoint, Inc. The Company recorded net revenue from contracts with WellPoint, Inc. of \$130.9 million for the nine months ended September 30, 2010. The Company's contracts with WellPoint, Inc. terminated on December 31, 2010.

11

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

By Segment

In addition to the Maricopa Contract previously discussed, the following customers generated in excess of ten percent of net revenues for the respective segment for the nine months ended September 30, 2010 and 2011 (in thousands):

Segment	Term Date	2010	2011
Commercial			
Customer A	December 31, 2012		
		\$ 189,949	\$ 131,633
Customer B	June 30, 2014	54,822	50,089
Customer C	June 30, 2012 to November 30, 2013(1)	40,303*	82,695
Public Sector			
Customer D	June 30, 2012(2)	113,540	135,597
Radiology Benefits Mana	gement		
WellPoint, Inc.	December 31, 2010(3)		
ti eni onit, nie.	2010(0)	119,155	
Customer E	November 30, 2012 to April 30, 2013(1)	84,435	100,575
Customer F	June 30, 2011 to November 30, 2011(1)(4)	50,982	34,271
Customer G	June 30, 2014	40,203	40,928
Customer H	March 31, 2013	4,057*	25,708
Specialty Pharmaceutical	Management		
Customer I	November 30, 2011 to March 31, 2012(1)	65,421	64,731
Customer J	September 1, 2011 to April 29, 2012(1)	43,246	41,704
Customer E	February 1, 2012 to April 30, 2013(1)	26,937	19,499*
Medicaid Administration	L		
Customer K	December 4, 2011(4)	23,531	22,193
Customer L	September 30, 2013(5)	6,647*	61,543
Customer M	September 30, 2011 to June 30, 2017(1)	17,905	18,635
Customer N	August 31, 2011 to June 30, 2013(1)	16,357	13,689*
Customer O	June 30, 2013 to September 30, 2014(1)	12,097	17,221

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Revenue amount did not exceed ten percent of net revenues for the respective segment for the period presented. Amount is shown for comparative purposes only.

(1) The customer has more than one contract. The individual contracts are scheduled to terminate at various points during the time period indicated above.

(2) Contract has options for the customer to extend the term for three additional one-year periods.

(3)

*

The contract has terminated.

12

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

(4)

The customer has informed the Company that this contract will not be renewed.

(5)

This customer represents a subcontract with a Public Sector customer and is eliminated in consolidation.

Concentration of Business

The Company also has a significant concentration of business with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program, and with various areas in the State of Florida (the "Florida Areas") which are part of the Florida Medicaid program. Net revenues from the Pennsylvania Counties in the aggregate totaled \$255.0 million and \$265.1 million for the nine months ended September 30, 2010 and 2011, respectively. Net revenues from the Florida Areas in the aggregate totaled \$106.0 million and \$100.0 million for the nine months ended September 30, 2010 and 2011, respectively.

The Company's contracts with customers typically have terms of one to three years, and in certain cases contain renewal provisions (at the customer's option) for successive terms of between one and two years (unless terminated earlier). Substantially all of these contracts may be immediately terminated with cause and many of the Company's contracts are terminable without cause by the customer or the Company either upon the giving of requisite notice and the passage of a specified period of time (typically between 60 and 180 days) or upon the occurrence of other specified events. In addition, the Company's contracts with federal, state and local governmental agencies generally are conditioned on legislative appropriations. These contracts generally can be terminated or modified by the customer if such appropriations are not made.

Fair Value Measurements

The Company currently does not have non-financial assets and non-financial liabilities that are required to be measured at fair value on a recurring basis. Financial assets and liabilities are to be measured using inputs from the three levels of the fair value hierarchy, which are as follows:

Level 1 Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 Unobservable inputs that reflect the Company's assumptions about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including the Company's data.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets and liabilities that are required to be measured at fair value as of December 31, 2010 and September 30, 2011 (in thousands):

	Fair Value Measurements								
	L	evel 1		Level 2	Level 3		Total		
Cash and Cash									
Equivalents(1)	\$		\$	68,726	\$	\$	68,726		
Restricted Cash(2)				72,698			72,698		
Investments:									
U.S. Government and									
agency securities		2,179					2,179		
Obligations of									
government-sponsored									
enterprises(3)				10,138			10,138		
Corporate debt securities				268,769			268,769		
Certificates of deposit				750			750		
Taxable municipal bonds				2,668			2,668		
-									
December 31, 2010	\$	2,179	\$	423,749	\$	\$	425,928		

	Le	vel 1	Level 2	Level 3	Total
Cash and Cash					
Equivalents(4)	\$		\$ 7,732	\$	\$ 7,732
Restricted Cash(5)			32,524		32,524
Investments:					
U.S. Government and					
agency securities		698			698
Obligations of					
government-sponsored					
enterprises(6)			11,161		11,161
Corporate debt securities			242,090		242,090
Certificates of deposit			200		200
September 30, 2011	\$	698	\$ 293,707	\$	\$ 294,405

(1)

Excludes \$268.5 million of cash held in bank accounts by the Company.

(2)

Excludes \$44.0 million of restricted cash held in bank accounts by the Company.

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

- (3) Includes investments in notes issued by the Federal Home Loan Mortgage Corporation and the Federal Home Loan Bank.

(4) Excludes \$134.7 million of cash held in bank accounts by the Company.

- (5) Excludes \$123.1 million of restricted cash held in bank accounts by the Company.
- (6)

Includes investments in notes issued by the Federal Home Loan Bank.

For the nine months ended September 30, 2011, the Company has not transferred any assets between fair value measurement levels.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

All of the Company's investments are classified as "available-for-sale" and are carried at fair value. Securities which have been classified as Level 1 are measured using quoted market prices while those which have been classified as Level 2 are measured using quoted prices for similar assets and liabilities in active markets. The Company's policy is to classify all investments with contractual maturities within one year as current. Investment income is recognized when earned and reported net of investment expenses. Net unrealized holding gains or losses are excluded from earnings and are reported, net of tax, as "accumulated other comprehensive income (loss)" in the accompanying consolidated balance sheets and consolidated statements of income until realized, unless the losses are deemed to be other-than-temporary. Realized gains or losses, including any provision for other-than-temporary declines in value, are included in the consolidated statements of income.

If a debt security is in an unrealized loss position and the Company has the intent to sell the debt security, or it is more likely than not that the Company will have to sell the debt security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in the consolidated statements of income. For impaired debt securities that the Company does not intend to sell or it is more likely than not that the Company will not have to sell such securities, but the Company expects that it will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment losses recognized in income in the consolidated statements of income and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income.

The credit component of an other-than-temporary impairment is determined by comparing the net present value of projected future cash flows with the amortized cost basis of the debt security. The net present value is calculated by discounting the best estimate of projected future cash flows at the effective interest rate implicit in the debt security at the date of acquisition. Cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings, and estimates regarding timing and amount of recoveries associated with a default. Furthermore, unrealized losses entirely caused by non-credit related factors related to debt securities for which the Company expects to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive income.

As of December 31, 2010 and September 30, 2011, there were no unrealized losses that the Company believed to be other-than-temporary. No realized gains or losses were recorded for the nine

15

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

months ended September 30, 2010 or 2011. The following is a summary of short-term and long-term investments at December 31, 2010 and September 30, 2011 (in thousands):

	А	mortized Cost	(Uni	December Gross realized Gains) Unr	010 Fross realized osses	 timated ir Value
U.S. Government and agency securities	\$	2,178	\$	1	\$		\$ 2,179
Obligations of government-sponsored enterprises(1)		10,142		7		(11)	10,138
Corporate debt securities		268,739		245		(215)	268,769
Certificates of deposit		750					750
Taxable municipal bonds		2,680				(12)	2,668
Total investments at December 31, 2010	\$	284,489	\$	253	\$	(238)	\$ 284,504

			Sep	tembe	r 30, 2011	
	A	mortized Cost	Gros Unreali Gain	zed	Gross Unrealized Losses	stimated air Value
U.S. Government and agency securities	\$	698	\$		\$	\$ 698
Obligations of government-sponsored enterprises(2)		11,160		4	(3)	11,161
Corporate debt securities		242,569		53	(532)	242,090
Certificates of deposit		200				200
Total investments at September 30, 2011	\$	254,627	\$	57	\$ (535)	\$ 254,149

(1)

Includes investments in notes issued by the Federal Home Loan Mortgage Corporation and the Federal Home Loan Bank.

(2)

Includes investments in notes issued by the Federal Home Loan Bank.

The maturity dates of the Company's investments as of September 30, 2011 are summarized below (in thousands):

	Amortized Cost	Estimated Fair Value
2011	\$ 92,150	\$ 92,062
2012	159,009	158,644
2013	3,468	3,443

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Total investments at September 30, 2011

\$ 254,627 \$ 254,149

Income Taxes

The Company's effective income tax rates were 40.3 percent and 34.0 percent for the nine months ended September 30, 2010 and 2011, respectively. These rates differ from the federal statutory income

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

tax rate primarily due to state income taxes, permanent differences between book and tax income, and changes to recorded tax contingencies. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes. The effective income tax rate for the nine months ended September 30, 2011 is lower than the effective rate for the nine months ended September 30, 2010 mainly due to more significant reversals of tax contingencies in the current year as a result of closure of statutes of limitation.

The Company files a consolidated federal income tax return for the Company and its eighty percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various states and local jurisdictions. With few exceptions, the Company is no longer subject to state or local income tax assessments by tax authorities for years ended prior to December 31, 2007. Further, the statutes of limitation regarding the assessment of federal and certain state and local income taxes for the year ended December 31, 2007 expired during the current quarter. As a result, \$9.6 million of unrecognized tax benefits (excluding interest costs) recorded as of December 31, 2010 was reversed in the current quarter as a result of statute expirations, \$8.1 million of which is reflected as a discrete adjustment to the effective rate.

Stock Compensation

At December 31, 2010 and September 30, 2011, the Company had equity-based employee incentive plans, which are described more fully in Note 6 in the Company's Annual Report on Form 10-K for the year ended December 31, 2010. The Company recorded stock compensation expense of \$3.6 million and \$11.8 million for the three and nine months ended September 30, 2010, respectively, and \$4.4 million and \$13.4 million for the three and nine months ended September 30, 2011, respectively. Stock compensation expense recognized in the consolidated statements of income for the three and nine months ended September 30, 2010 and 2011 has been reduced for estimated forfeitures, estimated at five percent and four percent, respectively.

The weighted average grant date fair value of all stock options granted during the nine months ended September 30, 2011 was \$12.94 as estimated using the Black-Scholes-Merton option pricing model, which also assumed an expected volatility of 29.9 percent based on the historical volatility of the Company's stock price.

The benefits of tax deductions in excess of recognized stock compensation expense are reported as a financing cash flow, rather than as an operating cash flow. In the nine months ended September 30, 2010 and 2011, \$0 million and \$2.1 million of benefits of such tax deductions related to stock compensation expense were realized and as such were reported as financing cash flows, respectively. For the nine months ended September 30, 2010 the change to additional paid in capital related to tax benefits (deficiencies) was \$(0.8) million. For the nine months ended September 30, 2011, the change to additional paid in capital related to tax benefits (deficiencies) was \$1.8 million which includes the \$2.1 million of excess tax benefits offset by \$(0.3) million of tax deficiencies.

17

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

Summarized information related to the Company's stock options for the nine months ended September 30, 2011 is as follows:

	Options	Av Ex	eighted verage xercise Price
Outstanding, beginning of period	3,775,586	\$	39.27
Granted	1,120,716		49.25
Forfeited	(29,306)		42.98
Exercised	(881,362)		38.35
Outstanding, end of period	3,985,634		42.26
Vested and expected to vest, end of period	3,891,114		42.16
Exercisable, end of period	1,835,319	\$	39.84

All of the Company's options granted during the nine months ended September 30, 2011 vest ratably on each anniversary date over the three years subsequent to grant, and all have a ten year life.

Summarized information related to the Company's nonvested restricted stock awards for the nine months ended September 30, 2011 is as follows:

	Shares	Av G	ighted erage rant Value
Outstanding, beginning of period	22,309	\$	39.23
Awarded	18,748		52.11
Vested	(22,309)		39.23
Forfeited			
Outstanding, ending of period	18,748	\$	52.11

Restricted stock awards granted during the nine months ended September 30, 2011 generally vest on the anniversary of the date of grant.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE A General (Continued)

Summarized information related to the Company's nonvested restricted stock units for the nine months ended September 30, 2011 is as follows:

	Shares	Av G	ighted verage Frant Stalue
Outstanding, beginning of period	190,488	\$	38.43
Awarded	112,543		49.10
Vested	(90,853)		37.50
Forfeited	(2,856)		45.12
Outstanding, ending of period	209,322	\$	44.49

Restricted stock units granted during the nine months ended September 30, 2011 generally vest ratably on each anniversary date over the three years subsequent to grant.

Long Term Debt and Capital Lease Obligations

On April 28, 2010, the Company entered into an amendment to its credit facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provided for an \$80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to \$30.0 million for revolving loans (the "2010 Credit Facility"). Borrowings under the 2010 Credit Facility mature on April 28, 2013. The 2010 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

Under the 2010 Credit Facility, the annual interest rate on Revolving Loan borrowings is equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 1.75 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 2.75 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 2.875 percent. The commitment commission on the 2010 Credit Facility is 0.50 percent of the unused Revolving Loan Commitment.

There were \$0.6 million of capital lease obligations at December 31, 2010 and September 30, 2011, respectively, \$44.9 million and \$36.2 million of letters of credit outstanding at December 31, 2010 and September 30, 2011, respectively, and no Revolving Loan borrowings at December 31, 2010 or September 30, 2011.



NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE B Net Income per Common Share

The following tables reconcile income (numerator) and shares (denominator) used in the computations of net income per common share (in thousands, except per share data):

	,	Three Moi Septem				Nine Mont Septem			
	2010 2011 20					2010	010		
Numerator:									
Net income	\$	44,784	\$	31,355	\$	105,731	\$	99,884	
Denominator:									
Weighted average number of common shares outstanding basic		33,450		29,900		33,715		31,406	
Common stock equivalents stock options		475		446		389		487	
Common stock equivalents warrants		157				150			
Common stock equivalents restricted stock		6		4		13		10	
Common stock equivalents restricted stock units		83		88		78		85	
Common stock equivalents employee stock purchase plan									
Weighted average number of common shares outstanding diluted		34,171		30,438		34,345		31,988	
Net income per common share basic	\$	1.34	\$	1.05	\$	3.14	\$	3.18	
Net income per common share diluted	\$	1.31	\$	1.03	\$	3.08	\$	3.12	

The weighted average number of common shares outstanding for the three and nine months ended September 30, 2010 and 2011 were calculated using outstanding shares of the Company's Ordinary Common Stock. Common stock equivalents included in the calculation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2010 and 2011 represent stock options to purchase shares of the Company's Ordinary Common Stock, restricted stock awards and restricted stock units, stock to be purchased under the Employee Stock Purchase Plan and shares of Ordinary Common Stock related to certain warrants issued on January 5, 2004.

The Company had additional potential dilutive securities outstanding representing 1.2 million and 1.9 million options, respectively, for the three and nine months ended September 30, 2010, and 1.1 million and 0.9 million options for the three and nine months ended September 30, 2011, respectively, that were not included in the computation of dilutive securities because they were anti-dilutive for the period. Had these shares not been anti-dilutive, all of these shares would not have been included in the net income per common share calculation as the Company uses the treasury stock method of calculating diluted shares.

NOTE C Business Segment Information

The accounting policies of the Company's segments are the same as those described in Note A "General." The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE C Business Segment Information (Continued)

income, gain on sale of assets, special charges or benefits, and income taxes ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Effective September 1, 2010, Public Sector has subcontracted with Medicaid Administration to provide pharmacy benefits management services on a limited risk basis for one of Public Sector's customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated. The Company's segments are defined above.

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

				F	Radiology			pecialty			С	orporate		
Three Months Ended			Public		Benefits	P	har	maceutical	_ I	Medicaid		and		
September 30, 2010	Co	ommercial	Sector	Ma	anagement	t l	Mai	nagement A	١dı	ministration	Eli	imination	Co	nsolidated
Net revenue	\$	165,270	\$ 364,102	\$	116,379		\$	68,609	\$	42,606	\$	(6,647)	\$	750,319
Cost of care		(84,485)	(310,261)		(72,980))				(6,081)		6,647		(467,160)
Cost of goods sold								(55,071)						(55,071)
Direct service costs		(40,156)	(17,554)		(17,366))		(8,064)		(27,928)				(111,068)
Other operating expenses												(30,513)		(30,513)
Stock compensation														
expense(1)		124	181		362			108		36		2,785		3,596
Segment profit (loss)	\$	40,753	\$ 36,468	\$	26,395		\$	5,582	\$	8,633	\$	(27,728)	\$	90,103

				adiology		Specialty			С	orporate		
Three Months Ended September 30, 2011	Co	mmercial	Public Sector	 	_	harmaceutical Management A	-	Medicaid ministration	Eli	and imination	Co	nsolidated
Net revenue	\$	135,365	\$ 362,104	\$ 78,659		\$ 73,792	\$	57,692	\$	(20,769)	\$	686,843
Cost of care		(81,503)	(318,807)	(49,186)			(19,324)		20,769		(448,051)
Cost of goods sold						(57,636)						(57,636)
Direct service costs		(36,582)	(16,741)	(14,717)	(6,563)		(26,221)				(100,824)
Other operating expenses										(29,214)		(29,214)
Stock compensation expense(1)		208	218	355		380		36		3,228		4,425
Segment profit (loss)	\$	17,488	\$ 26,774	\$ 15,111		\$ 9,973	\$	12,183	\$	(25,986)	\$	55,543

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2011

(Unaudited)

NOTE C Business Segment Information (Continued)

Nine Months Ended			Public		adiology Benefits		Specialty rmaceutical	I	Medicaid		porate and		
September 30, 2010	Commerc	ial	Sector	Ma	nagement	M	anagement A	Adı	ninistration	Elin	nination	Cons	olidated
Net revenue	\$ 487,9	54 \$	5 1,081,581	\$	331,099	\$	204,740	\$	121,303	\$	(6,647)	\$ 2,	220,030
Cost of care	(265,7	40)	(930,932)		(220,211)				(6,081)		6,647	(1,	416,317)
Cost of goods sold							(166,138)					(166,138)
Direct service costs	(115,3	40)	(50,559)		(47,605)		(19,537)		(94,555)			(327,596)
Other operating expenses										(91,856)		(91,856)
Stock compensation													
expense(1)	5	56	554		1,123		365		76		9,156		11,830
Segment profit (loss)	\$ 107,4	30 \$	5 100,644	\$	64,406	\$	19,430	\$	20,743	\$ (82,700)	\$	229,953

Nine Months Ended			Public		Radiology Benefits	Ph	Specialty armaceutical	l	Medicaid	С	orporate and		
September 30, 2011	Сог	nmercial	Sector	М	anagement	N	Aanagement .	Ad	ministration	Eli	imination	Co	nsolidated
Net revenue	\$	425,086	\$ 1,074,904	\$	258,479	\$	5 213,388	\$	167,622	\$	(61,543)	\$	2,077,936
Cost of care	((235,938)	(933,662)		(157,731)				(57,409)		61,543	((1,323,197)
Cost of goods sold							(167,559)						(167,559)
Direct service costs	((113,502)	(50,203)		(47,280)		(18,658)		(78,056)				(307,699)
Other operating expenses											(85,685)		(85,685)
Stock compensation													
expense(1)		677	654		1,238		639		100		10,100		13,408
-													
Segment profit (loss)	\$	76,323	\$ 91,693	\$	54,706	\$	27,810	\$	32,257	\$	(75,585)	\$	207,204

(1)

Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

The following table reconciles Segment Profit to income before income taxes (in thousands):